Moffitt Cancer Center has been awarded a four-year, $3 million grant from the Department of Defense’s Congressionally Directed Medical Research Programs to develop new treatments for rare melanomas, including uveal melanoma. The grant will fund two projects aimed at advancing targeted alpha-particle therapies.
Research to Prevent Blindness and Castle Biosciences today announced that they are partnering to increase opportunities for medical students to gain research experiences, specifically in the field of ocular cancer.
Scientists Dr. Cristina Puig-Saus and Dr. Daniel Shin from the UCLA Jonsson Comprehensive Cancer Center have received a $1 million Translational Research Award from the U.S. Department of Defense Melanoma Research Program to help advance the use of chimeric antigen receptor, or CAR, T cell therapy as a treatment for people with acral, mucosal and uveal melanomas.
MD Anderson and TriSalus announced a strategic research collaboration to evaluate the treatment of liver and pancreas tumors with the investigational therapy SD-101 in combination with immunotherapy using a novel delivery approach.